|
1
|
Shewach DS and Lawrence TS: Antimetabolite
radiosensitizers. J Clin Oncol. 25:4043–4050. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lawrence TS, Blackstock AW and McGinn C:
The mechanism of action of radiosensitization of conventional
chemotherapeutic agents. Semin Radiat Oncol. 13:13–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dai T and Shah MA: Chemoradiation in
oesophageal cancer. Best Pract Res Clin Gastroenterol. 29:193–209.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spithoff K, Cummings B, Jonker D and Biagi
JJ; Gastrointestinal Cancer Disease Site Group, : Chemoradiotherapy
for squamous cell cancer of the anal canal: A systematic review.
Clin Oncol (R Coll Radiol). 26:473–487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morris ZS and Harari PM: Interaction of
radiation therapy with molecular targeted agents. J Clin Oncol.
32:2886–2893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koning CC, Wouterse SJ, Daams JG,
Uitterhoeve LL, van den Heuvel MM and Belderbos JS: Toxicity of
concurrent radiochemotherapy for locally advanced non-small-cell
lung cancer: A systematic review of the literature. Clin Lung
Cancer. 14:481–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeVita VT, Lawrence TS and Rosenberg SA:
Cancer Principles and Practice of Oncology. Wolters Kluwer;
Philadelphia, PH: pp. pp2802015
|
|
8
|
Ivashkevich A, Redon CE, Nakamura AJ,
Martin RF and Martin OA: Use of the γ-H2AX assay to monitor DNA
damage and repair in translational cancer research. Cancer Lett.
327:123–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Radford IR: The level of induced DNA
double-strand breakage correlates with cell killing after
X-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med.
48:45–54. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown JM: The hypoxic cell: A target for
selective cancer therapy-eighteenth Bruce F. Cain Memorial Award
lecture. Cancer Res. 59:5863–5870. 1999.PubMed/NCBI
|
|
11
|
Bernier J, Hall EJ and Giaccia A:
Radiation oncology: A century of achievements. Nat Rev Cancer.
4:737–747. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Senkowski W, Zhang X, Olofsson MH, Isacson
R, Höglund U, Gustafsson M, Nygren P, Linder S, Larsson R and
Fryknäs M: Three-Dimensional cell culture-based screening
identifies the anthelmintic drug nitazoxanide as a candidate for
treatment of colorectal cancer. Mol Cancer Ther. 14:1504–1516.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Overgaard J: Hypoxic radiosensitization:
Adored and ignored. J Clin Oncol. 25:4066–4074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeVita VT Jr and Chu E: A history of
cancer chemotherapy. Cancer Res. 68:8643–8653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lindhagen E, Nygren P and Larsson R: The
fluorometric microculture cytotoxicity assay. Nat Protoc.
3:1364–1369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yeh PJ, Hegreness MJ, Aiden AP and Kishony
R: Drug interactions and the evolution of antibiotic resistance.
Nat Rev Microbiol. 7:460–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Santo N and Ehrisman J: A functional
perspective of nitazoxanide as a potential anticancer drug. Mutat
Res. 768:16–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muller J, Sidler D, Nachbur U, Wastling J,
Brunner T and Hemphill A: Thiazolides inhibit growth and induce
glutathione-S-transferase Pi (GSTP1)-dependent cell death in human
colon cancer cells. Int J Cancer. 123:1797–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rossignol JF and Maisonneuve H:
Nitazoxanide in the treatment of Taenia saginata and Hymenolepis
nana infections. Am J Trop Med Hyg. 33:511–512. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fan-Minogue H, Bodapati S, Solow-Cordero
D, Fan A, Paulmurugan R, Massoud TF, Felsher DW and Gambhir SS: A
c-Myc activation sensor-based high-throughput drug screening
identifies an antineoplastic effect of nitazoxanide. Mol Cancer
Ther. 12:1896–1905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stockis A, Deroubaix X, Lins R,
Jeanbaptiste B, Calderon P and Rossignol JF: Pharmacokinetics of
nitazoxanide after single oral dose administration in 6 healthy
volunteers. Int J Clin Pharmacol Ther. 34:349–351. 1996.PubMed/NCBI
|
|
23
|
Wurth R, Thellung S, Bajetto A, Mazzanti
M, Florio T and Barbieri F: Drug-repositioning opportunities for
cancer therapy: Novel molecular targets for known compounds. Drug
Discov Today. 21:190–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Santo N and Ehrisman J: Research
perspective: Potential role of nitazoxanide in ovarian cancer
treatment. Old drug, new purpose? Cancers (Basel). 5:1163–1176.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brockmann A, Strittmatter T, May S,
Stemmer K, Marx A and Brunner T: Structure-function relationship of
thiazolide-induced apoptosis in colorectal tumor cells. ACS Chem
Biol. 9:1520–1527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hemphill A, Mueller J and Esposito M:
Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for
the treatment of gastrointestinal infections. Expert Opin
Pharmacother. 7:953–964. 2006. View Article : Google Scholar : PubMed/NCBI
|
